Oxlumo
Oxlumo ingredients
| Active ingredient | Strength |
|---|---|
| Lumasiran Sodium | 94.5 mg/.5mL |
What Oxlumo is used for
The FDA lists the approved uses on the official label (below). In the EU, lumasiran is approved as Oxlumo for:
Treatment of primary hyperoxaluria type 1 (PH1) in all age groups.
EU wording from the European Medicines Agency; US approved uses can differ.
Key facts
- Brand
- Oxlumo
- Generic name
- Lumasiran
- Made by
- Alnylam Pharmaceuticals, Inc.
- Forms
- Injection, Solution
- Given
- Subcutaneous
- FDA approval
- New drug application (NDA) NDA214103
- On the US market since
- 2020
Official information
- Oxlumo prescribing information (FDA label) on DailyMed
- MedlinePlus drug information (search for Lumasiran)
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Oxlumo?
Oxlumo (Lumasiran) is a specialist medicine made by Alnylam Pharmaceuticals, Inc., approved by the US FDA.
What are the ingredients of Oxlumo?
Oxlumo contains Lumasiran Sodium (94.5 mg/.5mL).
Is Oxlumo approved in Europe?
The same active substance is approved in the EU as Oxlumo.
From the FDA National Drug Code directory (open.fda.gov, public domain) and the European Medicines Agency medicines list. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, USA